

Effective Delivery of Pharmaceutical Palliative Care: Challenges in the Community Pharmacy Setting.

Akram G, Bennie M, McKellar S, Michels S, Hudson S and Trundle J.

Abstract (250 words)

Purpose: The important role played by clinical pharmacists in the delivery of hospital based palliative care services is well documented. However, the evidence base supporting the role of the community pharmacist is limited. This study describes the challenges facing community pharmacists operating in a local palliative care network in Scotland.

Methods: Qualitative data were gathered using focus group interviews. Participants were identified from members of a Community Pharmacy Palliative Care Network attending scheduled training events. Thirty five pharmacists were recruited to one of five group interviews each lasting between 60 and 90 minutes. The interviews were recorded and transcribed verbatim. The transcripts were analysed using the Framework Approach.

Results: Three key themes emerged: medication supply; communication; education and training. Challenges to the medication supply process included: the presentation of prescriptions for medication not listed in the locally agreed stock list; the out-of- hours period; balancing legal and ethical considerations when supplying controlled drugs; and transferring medicines between locations. Communication was critical to service delivery and found to be lacking, especially when patients were transferred between care settings. Education and training of pharmacy staff, particularly locums and counter staff, and better awareness of the Network by the broader palliative care team was also identified.

Conclusions: This study has informed the development of an evidence-based action plan for the Macmillan Pharmacist Facilitators. The plan focuses on: raising awareness and integration of the Network; providing training across the palliative care team; developing prescribing tools to aid clinicians; and exploring models for information sharing.

1 **Introduction (2879 words)**

2 Medication, particularly analgesia is an important component of palliative care. However,
3 timely access to medication, particularly opioids, can become problematic for patients
4 receiving palliative care in the community setting^{1,2,3}. Medication related problems appear to
5 be common place and occur regardless of the health care system in operation^{1,4,5}. For example,
6 49% (n=28/53) of community pharmacists surveyed in the North Dublin area⁴, reported ‘not
7 having the medication in stock’ as a major factor causing delay in supply of medication to
8 patients. In Japan⁵, only 77% of community pharmacists have a ‘narcotics retailer license’
9 thereby limiting the availability of pharmacies from where prescriptions for opioid pain relief
10 could be dispensed.

11
12 In Scotland, an audit of palliative care services⁶ found that access to medication, particularly
13 unlicensed drugs was a problem for some patients. Consequently, under the Model Schemes in
14 Pharmaceutical Care initiative⁷, a Community Pharmacy Palliative Care (CPPC) Network was
15 established in each Scottish Health Board area. Pharmacies in the CPPC Network were
16 expected to provide an enhanced pharmaceutical palliative care service. This was achieved by
17 the Pharmacy: retaining a stock of specialised palliative care medication; arranging
18 transportation of urgently required medicines and supporting non-Network Pharmacies,
19 General Practitioners (GPs) and District Nurses within their local areas. A subsequent review⁸,
20 five years later, of palliative care services found that although the majority of CPPC Network
21 Pharmacies were now carrying the additional stock of palliative care medicines, some issues
22 remained. These included patients’ being denied access to urgently required medicines,
23 particularly Controlled Drugs out-of-hours (after 6pm and at weekends) and after discharge
24 from hospital. In 2009, NHS Greater Glasgow & Clyde Health Board (NHS GG&C), in
25 partnership with Macmillan Cancer Support, established a programme to improve the local
26 provision of pharmaceutical palliative care services. Four Macmillan Pharmacist Facilitators
27 were appointed, part time, to work in 4 localities in the West of Scotland. The localities
28 covered a total population of approximately 430,000 and comprised 112 community
29 pharmacies. Twenty six of these pharmacies were members of the local CPPC Network.
30 Researchers at the University of Strathclyde were commissioned to support the development
31 and evaluation of this new service. A key early task for the facilitators was to understand the
32 provision of palliative care services currently provided by CPPC Network Pharmacies. This
33 paper reports the findings of this initial investigation and outlines an evidence-based action
34 plan to support service improvement.

35 36 **Methods**

37 Qualitative data were gathered using focus group interviews. This method was chosen because
38 the group interview allows participants to articulate their thoughts, opinions, and attitudes, in a
39 relatively ‘naturalistic’ setting⁹. The technique is also commonly used for collecting
40 information about health service practice and delivery^{10,11}. A topic guide enquiring about
41 participants’ experiences of providing palliative care services and of being in the CPPC
42 Network was developed and used. Ethics approval was sought but deemed unnecessary, since
43 the project was an evaluation of current service delivery. The principles of informed consent
44 and good ethical practice were applied and observed. The focus groups were facilitated by
45 three members of the university team who are also authors of the paper.

46
47 Participants were identified from amongst those attending scheduled training events for CPPC
48 Network Pharmacies during January and February 2010. Thirty five pharmacists were
49 recruited to one of five focus groups each lasting between 60 and 90 minutes. The interviews
50 were recorded and transcribed verbatim. The transcripts were independently read by the three
51 authors and subjected to a thematic analysis using the Framework Approach^{12,13}. Identified

52 emergent and recurrent themes were coded according to the appropriate thematic reference and
53 validated by team members through consensus.

54

55 **Results**

56 Three key themes were identified: medication supply; communication; and education and
57 training. The themes are discussed below with participants quotes used to illustrate the
58 findings.

59

60 *1. MEDICATION SUPPLY*

61 Discussion of the medication supply process identified four sub-themes relating to the
62 prescribing or dispensing of medicines.

63 a) Unfamiliar medicines

64 Most participants had experience of being presented with prescriptions containing medicines
65 which were not listed in the locally agreed palliative care stocklist. Such products were
66 unlikely to be routinely stocked in the pharmacy. This often meant that the prescriber would
67 need to be contacted for clarification, resulting in delays with supplying the medication.

68

69 *“Somebody prescribed Hyoscine the other week; it was a 600 mcg ampoule whereas we*
70 *always keep 400 mcg, that’s what’s on the list [palliative care stock list]. You then*
71 *have to phone, chase up the doctors to get it changed”.*

72

73 b) Prescriptions presented out-of-hours

74 Almost all the participants identified the out-of-hours period as being more vulnerable to
75 problems occurring. At these times it can be more difficult to contact relevant personnel for
76 prescription clarification and to get access to medicines which may need to be specially
77 ordered. Additionally, at these times, the Pharmacy may be staffed by individuals not usually
78 employed during the routine working day and thus may be unfamiliar with elements of the
79 service.

80

81 *“I think that is where it falls down because it’s our pharmacies that are part of the*
82 *scheme but we are not there as palliative pharmacists when we are needed most, which*
83 *is at the weekend and ‘out of hours’”.*

84

85 c) Legal versus ethical dilemmas

86 Participants also discussed the issues they face when presented with a prescription that does
87 not comply with the legislation. In particular for Controlled Drugs, which need to be written in
88 accordance with the regulations. If the prescription is incomplete, it needs to be referred back
89 to the prescriber before dispensing, potentially causing delay. The interviews illustrated the
90 serious professional and ethical quandary faced by the pharmacists that the rest of the palliative
91 care team and patients are likely to be unaware of:

92

93 *“This morning I had a prescription for diamorphine and it said ‘to be used as directed’.*
94 *I knew the patient was very ill but I had a prescription without the full information, so it*
95 *was a bit of a dilemma about how to proceed”.*

96

97 *“If it’s urgent then you’ve got to weigh up the benefits, this patient is either going to be*
98 *in pain or you just give them it, as long as you can defend yourself”.*

99

100 d) Transfer of medicines between settings

101 The Taxi Protocol, whereby local taxis may be used to collect and deliver urgent medicines
102 between pharmacies and patients was considered a helpful resource, but was used infrequently.

103 Some participants stated that the protocol was a complicated bureaucratic procedure. They
104 preferred to deliver the medicines themselves and use the opportunity to counsel or offer
105 support to the patient. Some also expressed reservations about handing medicines, especially
106 Controlled Drugs to non-healthcare staff:

107
108 *“You wouldn’t use the taxi protocol cause you need to look out the palliative care*
109 *folder, and the right paperwork, then you need to find the tags and the bags, then phone*
110 *the taxi company, then you need to make sure it’s got there, then get your bag back. It’s*
111 *a palaver”.*

112
113 *“Personally I just feel safer with one of my staff or I doing it than just handing it over*
114 *to a taxi driver. Even though there is a protocol set up for it, I just don’t feel*
115 *comfortable with that, especially if it’s a controlled drug”.*

116 117 2. COMMUNICATION

118 Communication across the palliative care team was seen as an important factor impacting on
119 service delivery. District Nurses were recognised as an invaluable source of information about
120 the patients’ clinical condition and medicine requirements. Some participants seemed to feel
121 that the District Nurses had a better appreciation of the potential for prescription related
122 problems to occur. They would try to minimise these where possible, for example by
123 contacting the pharmacy in advance to pre-empt supply problems and guiding patients/carers to
124 Network Pharmacies where appropriate. However, the discussions revealed that
125 communication was particularly poor between care settings, especially when patients were
126 admitted to or discharged from hospital/hospice. Some pharmacists reported being ill informed
127 of changes that had occurred to the patient’s regular prescriptions:

128
129 *“It’s a problem when they’re [the patients] discharged. I have people come in saying*
130 *‘I’ve been out of hospital for a week and I need medicine for tomorrow and all my*
131 *medications have changed’ and I have got no discharge letter and no idea what the*
132 *medication is that’s changed”.*

133
134 Such problems may be amplified through the use of weekly monitored dosage systems (MDS).
135 These can be labour intensive as they require individual doses to be dispensed into
136 compartments separated by day and time. Almost all the participants had experience of
137 preparing or delivering MDS to patients that had been admitted to hospital or had passed away.

138
139 *“It’s not unusual for us to have been delivering Dosesettes© to patients week after week*
140 *and someone phones up to say, “my father passed away three weeks ago, can you stop*
141 *delivering” and we say, “we’re very sorry but we didn’t know, no-one’s informed us”.*

142
143 Membership of the Network was seen as supportive but could also present a challenge.

144
145 *“The reassurance that there is support out there, if something a bit more unusual*
146 *comes up, then you know where to go; you’re not on your own”.*

147
148 Most participants agreed with a pharmacist, who suggested that sometimes, it is difficult to
149 provide an optimum service to individuals who present at a Network Pharmacy with minimal
150 information:

151
152 *“You pick up patients in the final stages of their life who aren’t your regulars and you*
153 *don’t know anything about them. You’ve got no Patient Medication Record to check and*

154 *see what doses they've been on, it really is a prescription out of the blue, you've got no*
155 *back up to know that you are dispensing the right thing".*
156

157

158 3. EDUCATION AND TRAINING

159 For some participants, the limited knowledge and understanding of their role by palliative care
160 team members, was a key factor affecting their provision of services to patients and carers.

161

162 *"I don't think a lot of GPs know who the palliative care pharmacies are, let alone what*
163 *we stock"*
164

165

165 Participants also expressed a need for better training of their own staff, particularly counter
166 assistants and locum pharmacists. Counter assistants were identified as the first point of
167 contact in the dispensing process. If their ability to recognise urgent palliative care
168 prescriptions was improved then this could avoid unnecessary delays for patients and carers:

169

170 *"It's usually the counter staff who deal with [incoming] prescriptions so they've got to have*
171 *some understanding of what's a palliative care drug and what's not; if they know what's a*
172 *controlled drug they could ask further questions. Otherwise, it [the prescription] could get*
173 *lost in the dispensary, you might not see it".*
174

175

175 The participants reported that locum pharmacists may be unaware that a pharmacy is part of
176 the CPPC Network and what is expected of them. Whilst there was recognition of the
177 difficulty in implementing training for locums, all agreed that this should be put in place to
178 build on the pharmacist's core knowledge.

179

180 *"A [resource] pack for locums ... just to give them a bit of confidence in what they're*
181 *doing if they're on their own".*
182

183

183 Availability of routine resources for pharmacists to support clinical practice was highlighted.
184 Standard references including the British National Formulary were mentioned but were
185 identified as limited in providing specific palliative care information. The Palliative Care
186 Formulary (also known as the PCF3) was found to be invaluable in identifying and cross-
187 referencing unlicensed indications and doses of medicines¹⁴. During out-of-hours most
188 participants reported that they would contact local hospices or specialist hospital pharmacists
189 and the NHS 24 professional-to-professional service for advice or information¹⁵. The internet
190 was also discussed but the practicalities of accessing and browsing web pages whilst being
191 fully engaged in the workings of a busy community pharmacy were seen as major obstacles:

192

193 *"The paper on the shelf is accessible - the computer's being used, someone's printing,*
194 *you want to get on the internet or whatever - it can be time-consuming, restrictive.*
195 *Whereas the reference on the shelf, you pick it up, it's there in black and white - you're*
196 *not scrolling up and down the screen".*
197

198

199

199 Discussion

200 In the hospital/hospice setting, pharmacists are routinely part of the clinical team and involved
201 in the care planning process^{16,17,18}. Needham et al¹⁹ reported on the beneficial role of
202 community pharmacists in a small in-depth case series analysis. However, the evidence base
203 supporting the role of the community pharmacist in palliative care service delivery is generally
204 limited as highlighted in a recent editorial²⁰. This paper adds to the literature by reporting a

205 model currently operating in Scotland. It provides an insight into challenges facing community
206 pharmacists in their delivery of palliative care services.

207
208 Exploration of the medicines supply process identified issues that were out-with the
209 pharmacist's control, most notably, incorrectly written prescriptions. This finding concurs
210 with the study by Lucey et al⁴ in which Community Pharmacists cited "incorrectly written or
211 illegible prescriptions" as factors impinging on their delivery of service. Additionally, our
212 study uncovered a significant ethical dilemma for pharmacists which is associated with the
213 supply of medicines when the prescription does not meet the legal requirements. Education of
214 both the palliative care team and patients/carers of the need for legally compliant prescriptions
215 could help to minimise delays in medicines supply and hence avoid the distress to patients and
216 carers.

217
218 An interesting finding, particularly for service managers, was participants' reluctance to
219 implement the Taxi Protocol. The protocol can be used in urgent situations to collect a
220 prescription form, or collect or deliver medication between pharmacies or to the patient's
221 home. It had been introduced with the involvement of CPPC Network pharmacists, following
222 reflection on incidents where there had been delays in obtaining or dispensing medicines, and
223 hence, in symptom control, with ensuing distress to families and professionals. It did appear,
224 to be viewed as bureaucratic. However, it was encouraging to find that some pharmacists said
225 they would prefer to deliver the medicines themselves, to make direct contact with the patient
226 and offer advice or support.

227
228 The unpredictable nature of disease trajectory and the diversity of the palliative care team
229 necessitates good communication^{21,22}. Our study highlights where poor communication can
230 impact on patient care, particularly between care settings and across the palliative care team.
231 Robust mechanisms for the transfer of clinical information between services and health
232 professionals are therefore required. The out-of-hours period is known to be particularly
233 problematic²³ and this was confirmed in our study. One solution being explored in Scotland is
234 to give Community Pharmacists access to the NHS ePCS (electronic Palliative Care
235 Summary). The ePCS contains information about the individual's medical condition, treatment,
236 'carers' details and their 'wishes' concerning treatment towards the end of life²⁴. Another
237 potential source of information sharing is the 'Supportive Care Register'. This is one of the
238 documents used in the application of the Gold Standards Framework (Scotland), which is a
239 programme based in General Practice to support planning and communication for patients
240 receiving palliative care in the community²⁵. Access to it would allow Community
241 Pharmacists to make appropriate and safe medication-based interventions. It would be
242 particularly helpful when a patient is specifically referred to a pharmacy because of their
243 palliative care needs.

244
245 Improved information sharing could also be addressed through attendance of pharmacists at
246 clinical palliative care team meetings. Attendance of pharmacists at clinical review sessions
247 are known to improve patient outcomes in palliative care and other specialties^{17,26,27}. However,
248 the practicalities and logistics involved, particularly for single-handed pharmacists, make this
249 challenging in the community setting. The peripatetic nature of the Macmillan Pharmacist
250 Facilitators may provide an opportunity; either by attendance at team meetings and
251 disseminating the information to the Community Pharmacist or by providing cover in the
252 pharmacy to enable the community pharmacist to attend the team meetings.

253
254 Training, particularly of pharmacy support staff, to enable more effective engagement with
255 patients, carers and health professionals was recognised as an area for action. Small changes

256 such as being able to identify a palliative care prescription when it is first presented would
257 allow early identification of potential problems. Inclusion of counter staff within CPPC
258 Network training events should provide better understanding of patients' needs resulting in a
259 more effective and responsive service.

260
261 The qualitative nature of the study poses limitations regarding generalisability and
262 reproducibility. Nevertheless, our intention was to provide an insight into issues faced by
263 Community Pharmacists in their delivery of palliative care services. A comparative study with
264 non-Network pharmacists would have given a more comprehensive description. However, we
265 believe that this study provides a baseline upon which improvements to service provision can
266 be developed. The overlap and commonalities between this and the few other studies
267 investigating community pharmacy service delivery^{4,5} suggest that our findings are not unique
268 to our sample or the geographical area.

269
270 **Conclusions**
271 This study describes the challenges facing community pharmacists in their delivery of
272 palliative care services. These findings have been used to develop an evidence based action
273 plan for the Macmillan Pharmacist Facilitators. This programme of work is due for completion
274 by December 2012 and includes the following:

- 275 • To raise awareness and integration of CPPC Network pharmacies within their localities
276 and the broader Community Pharmacy family.
- 277 • To provide training to key staff groups including pharmacy support and locum
278 pharmacists.
- 279 • To develop prescribing tools to aid GPs with medicines selection and correct
280 prescribing of Controlled Drugs used in palliative care.
- 281 • To explore different models for information sharing between General Practice and
282 Community Pharmacy.

Acknowledgments

The authors would like to thank all the Pharmacists who participated in the study, the Macmillan Pharmacist Facilitators, (Carolyn Mackay, Karen Menzies, Nadia Afzal, Annamarie McGregor), the Macmillan Project Evaluation Group and Project Steering Group.

This paper is dedicated to the memory of Professor S. Hudson.

Author Disclosure Statements

No competing financial interests exist.

References

1. Greenwald, BD & Narcessian EJ. Opioids for managing patients with chronic pain: Community pharmacists' perspectives and concerns. *J Pain Symptom Manage* 1999; 17:369-375
2. Kanner RM & Portenoy RK. Unavailability of narcotic analgesics for ambulatory cancer patients in NYC. *J Pain Symptom Manage* 1986;1: 87-89
3. Holdsworth MT, Raisch DW. Availability of narcotics and pharmacists attitudes toward narcotic prescriptions for cancer patients. *Ann Pharmacother* 1992; 26: 321-326
4. Lucey M, McQuillan R, MacCallion A, Corrigan M & Connaire K. Access to medications in the community by patients in a palliative setting: A systems analysis. *Palliat Med* 2008; 22:185-189
5. Ise Y, Morita T, Maehori N, Kutsuwa M, Shiokaw M & Kizawa Y. Role of the Community Pharmacist in Palliative Care: A Nationwide Survey in Japan. *J Pall Med* 2010;13: 733-737.
6. Healthcare Improvement Scotland. Clinical Standards: Specialist Palliative Care. 2002. (www.healthcareimprovementscotland.org/previous_resources/standards/specialist_palliative_care.aspx). (Accessed May 2011)
7. Scottish Executive Health Department. MEL (1999). 78. Community Pharmacy: Model Schemes for Pharmaceutical Care.
8. Audit Scotland. Review of Palliative Care Services in Scotland. 2008. (www.audit-scotland.gov.uk/docs/health/2008/nr_080821_palliative_care.pdf). (Accessed May 2011)
9. Green J. The use of Focus Groups in Research into Health In: Saks M, Allsop J, Eds. *Researching Health: Qualitative, Quantitative and Mixed Methods*. 2007. London: Sage Publications; 113-132.
10. Smith FJ. Health Services Research Methods in Pharmacy: Qualitative Interviews. *Int J Pharm Pract* 1998;6:97-108
11. Britten N. Qualitative Interviews in Health Research. In: Pope C, Mays N, Eds. *Qualitative Research in Health Care*. 3rd ed. 2006. Oxford: Blackwell Publishing Ltd; 12-20
12. Pope C, Ziebland S, & Mays N. Qualitative Research in Health Care: Analysing qualitative data. *BMJ* 2000;320:114-6

13. Richie J & Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess R,G (Eds). *Analysing Qualitative Data*. 1st ed. 1994. London: Routledge; 173-94
14. Twycross R & Wilcock A. *Palliative Care Formulary (PCF3)*. 3rd edition. 2007. palliativedrugs.com.
15. NHS 24. Health information and self care advice for Scotland. (www.nhs24.com/content/default.asp?page=home). (Accessed May 2011).
16. Burch, PL & Hunter KA. Pharmaceutical care applied to the hospice setting: a cancer care model. *Hospice J* 1996;11:55-69
17. Lucas C, Glare PA & Sykes JV. Contribution of a liaison clinical pharmacist to inpatient palliative care unit. *Palliat Med* 1997;11:209-16
18. Gilbar P & Stefaniuk K. The role of the pharmacists in Palliative Care: Results of a survey conducted in Australia and Canada. *J Palliative Care* 2002;18:287-292.
19. Needham DS, Wong IC & Campion PD. Evaluation of the effectiveness of UK community pharmacists interventions in community palliative care. *Palliat Med* 2003;16:219-225
20. O'Connor M, Pugh J, Jiwa M, Hughes J & Fisher C. The Palliative Care Interdisciplinary Team: Where is the Community Pharmacist? *J Palliat Med* 2011;14:7-11
21. Eastaugh AN. Approaches to palliative care by primary healthcare teams: *J Palliat Care* 1996;12: 47-50
22. Barclay S, Rogers M & Todd C. Communication between GPs and co-operatives is poor for terminally ill patients. *BMJ* 1997;315:1235-36
23. Gray N, Allanson H & Reeves N. Access to medicines out of hours- the views of service users and carers. *Pharm J* 2008; 281: 447a
24. Scottish Government. *The electronic Palliative Care Summary (2009)*. (www.scimp.scot.nhs.uk/documents/ePCSPatientInformationLeaflet.pdf). Accessed May 2011
25. NHS Scotland. *Gold Standards Framework (Scotland)*. <http://www.gsfs.scot.nhs.uk/index.html>. Accessed June 2011
26. Finley PR, Crimson ML & Rush AJ. Evaluating the Impact of Pharmacists in Mental Health. *Pharmacotherapy* 2003;23:1634-644
27. Schumock GT, Butler MG, Meek PDC, Arondekar B & Bauman JL. Evidence of economic benefit of clinical pharmacy services: 1996-2000. *Pharmacotherapy* 2003; 23: 113-32